CN1720941A - Compound medicinal preparation with clopidogrel and red rice extracts and application thereof - Google Patents
Compound medicinal preparation with clopidogrel and red rice extracts and application thereof Download PDFInfo
- Publication number
- CN1720941A CN1720941A CN 200510084327 CN200510084327A CN1720941A CN 1720941 A CN1720941 A CN 1720941A CN 200510084327 CN200510084327 CN 200510084327 CN 200510084327 A CN200510084327 A CN 200510084327A CN 1720941 A CN1720941 A CN 1720941A
- Authority
- CN
- China
- Prior art keywords
- clopidogrel
- monas cuspurpureus
- cuspurpureus went
- pharmaceutical composition
- bifendate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to a medicinal composition comprising effective dose of red yeast rice extract and at least a medicament for resisting platelet aggregation, especially compound medicinal preparation of Clopidogrel red yeast rice extract and its use, the preparation can also contain right amount of liver-protective agent, and at least one kind of pharmaceutically acceptable excipient.
Description
Technical field:
The present invention relates to a kind of compound medicament composition, particularly relate to the pharmaceutical composition that the Monas cuspurpureus Went extract that contains effective dose and at least a anti-platelet aggregation medicine are formed, also can add an amount of hepatic in case of necessity, and at least a pharmaceutically acceptable excipient.
Background technology:
Monas cuspurpureus Went records in the Pharmacopoeia of the People's Republic of China, " Chinese medicine voluminous dictionary " as Chinese crude drug.Describe the red song of Monas cuspurpureus Went different name, be inoculated on the rice by monascus and form through fermenting process of preparing.In recent years, relevant scholar deepens continuously to the research of Monas cuspurpureus Went both at home and abroad, has found that the effective ingredient in the Monas cuspurpureus Went mainly contains: cholesterol synthetic inhibitor (lovastatin), unsaturated fatty acids, alcohols and ester type compound, multiple pigment, material for lowering blood pressure (GABA), anti-putrefaction bacteria material (MonacolinK), the Natural antioxidant: as dimemmicac5d and flavone phenol, blood sugar lowering and other biological active substanceies that waits to identify.
China starts from the eighties in last century in the research to natural Antilipemic monascus, and first has released accent fat new drug---the zhibituo sheet that the Monas cuspurpureus Went that lovastatin is arranged is the single composition buchu drugmaker.Beijing University's dimension believes that developing with the Monas cuspurpureus Went extract that contains the lovastatin chemical compound again is the medicine of main component---XUEZHIKANG JIAONANG subsequently.
The main component of these two kinds of medicines all contains the Monas cuspurpureus Went extract of lovastatin.Have some outstanding features, particularly compare with simple lovastatin, under the situation that contains identical lovastatin dosage, Monas cuspurpureus Went has stronger blood fat reducing comprehensive therapeutic effect, also can reduce and take stanin fat-reducing medicament for a long time and issuable toxic and side effects, its potency ratio tallies with the national condition.Monas cuspurpureus Went extract is considered to have the very blood fat reducing material of future.Vast amount of clinical shows Monas cuspurpureus Went extract energy hypercholesterolemia reducing, reduces low-density lipoprotein cholesterol, reduces serum triglycerides, reduces atherogenic index, the high density lipoprotein increasing cholesterol, thereby effectively treat cardiovascular and cerebrovascular diseases and the disease relevant such as coronary heart disease, apoplexy, as diabetes, the nephrotic syndrome and fatty liver with hyperlipidemia.This medicine is taken safe, and toxic and side effects is little, by chance having the patient serum glutamic pyruvic transminase to occur during clinical practice slightly raises, alanine aminotransferase/aspartate transaminase surpasses slightly the raise situation of (0.12%) of upper limits of normal 3 times (0.06%) and creatine phosphokinase, but after the drug withdrawal, all can return to the preceding level of medication.Not only contain MonacolinK in the Monas cuspurpureus Went extract, also contain ubiquinone, can reduce the similar side effect of statins.
The at present domestic crude drug that has had the Duo Jia pharmaceutical factory to produce Monas cuspurpureus Went extract.The preparation method of Monas cuspurpureus Went extract crude drug is many, and market is on sale.The Monas cuspurpureus Went extract that the present invention uses is that dimension letter biotechnology company of Beijing University extracts the medicine material product that forms from special Chinese medicine Monas cuspurpureus Went and rice fermentation product, and its lovastatin content is 15～20mg/g; The unsaturated fatty acid total amount is more than 80%.
The anti-platelet aggregation medicine can suppress hematoblastic release (release that causes as epinephrine, collagen and thrombin etc.) and assemble, and prolongs the bleeding time, reduces thrombosis, also can suppress the biosynthesis of cholesterol, reduces low-density lipoprotein cholesterol.Clopidogrel is a main medicament for resisting platelet aggregation, all goes on the market both at home and abroad.Suppress adenosine diphosphate (ADP) and combine, thereby prevent platelet aggregation by changing glycoprotein GPIIb/IIIa with platelet adp receptor; Optionally suppress the enhancing of other agonism of inductive platelet aggregation of adenosine diphosphate (ADP) and adenosine diphosphate (ADP) participation; Suppress platelet adhesion and the subendothelial layer that is gathered in damaged.Clopidogrel must be behind biotransformation, though can not suppress the activity of phosphodiesterase, suppress hematoblastic accumulative effect but can bring into play, and this inhibitory action is dose dependent by the amplification of blocking the platelet activation that causes by the adenosine diphosphate (ADP) that discharges.
Bifendate is a kind of intermediate of synthetic schisandrin C, can alleviate serum alanine aminotransferase and raise to the influence of liver function, can also strengthen the function of detoxification of liver, promotes the function of stem cell regenerating.
At present clinically, be primarily aimed at the antithrombotic that symptom is carried out simple property, or the blood fat reducing of simple property treatment, but its curative effect is all very undesirable.For solving drug safety, convenient, effectively, reduce the problem of side effect, the invention provides the compound medicament composition that clopidogrel and Monas cuspurpureus Went extract are formed.But in order to ensure drug safety, also can in compound preparation, add at least a hepatic, thereby make the incidence rate of hepar damnification reduce to minimum.
Pharmaceutical composition of the present invention, contain plurality of active ingredients: Monas cuspurpureus Went extract and anti-platelet aggregation medicine add an amount of hepatic in case of necessity, can cholesterol reducing, but anti-platelet aggregation is alleviated atherosclerosis, but also is had the comprehensive therapeutic effect that improves liver function again.
Summary of the invention:
The invention provides a kind of pharmaceutical composition, contain the Monas cuspurpureus Went extract and at least a anti-platelet aggregation medicine of effective dose in the said composition, also can add at least a hepatic as required.
Pharmaceutical composition of the present invention, the Monas cuspurpureus Went extract that wherein contains is bought the dimension letter biotechnology company in Beijing University; The anti-platelet aggregation medicine is selected from: aspirin, troxerutin, dipyridamole, clofibrate, ticlopidine, sulfinpyrazone, cilostazol, indobufen, clopidogrel, ozagrel, epoprostenol, Beraprost or dazoxiben, preferably clopidogrel; Hepatic is selected from: bifendate, adenosine triphosphate disodium salt, inosine, glucuronolatone, diisopropylamine dichloroacetate or have the vitamin of hepatoprotective effect, preferably bifendate.
Compositions of the present invention is that the pharmaceutical dosage forms with unit dose exists, and contains the anticoagulation medicine of 30～150mg in the pharmaceutical preparation of unit dose, as Monas cuspurpureus Went extract and the clopidogrel 30～150mg of 100～500mg.
Compositions of the present invention preferably contains the Monas cuspurpureus Went extract of 200～300mg and the clopidogrel of 50～100mg in the pharmaceutical preparation of unit dose.
Compositions of the present invention, the content combination of each composition of preparation of most preferred unit dose sees Table 1.
The combination agent scale of table 1 compound recipe clopidogrel Monas cuspurpureus Went extract
Also can contain at least a hepatic in the compositions of the present invention, preferably bifendate contains 10～50mg bifendate, preferably the bifendate of 10～30mg in the pharmaceutical preparation of unit dose.
Optimum dose combination in the compositions of the present invention behind the adding hepatic can see Table 2.
The combination agent scale of table 2 compound recipe clopidogrel Monas cuspurpureus Went extract
The pharmaceutical preparation of the above unit dose is meant final drug preparation unit, as every of tablet, and capsular every, every bag of granule etc.
Compositions of the present invention, preferably oral pharmaceutical preparation is as conventional tablet, enteric coatel tablets, dispersible tablet, chewable tablet, conventional capsule, soft capsule, enteric coated capsule, granule etc.
Compositions of the present invention also can add drug excipient in case of necessity, comprising: one or more in the pharmaceutical adjunct that filler, binding agent, disintegrating agent, lubricant, correctives, coloring agent etc. are used always.
Tablet, capsule, particles filled dose can be selected microcrystalline Cellulose, lactose, mannitol, calcium carbonate, starch etc.; Binding agent preferably has the polymer of high-consistency, can select polyvidone, methylcellulose, hydroxy methocel, ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, starch slurry etc.; Optional the choosing friends of disintegrating agent joins polyvidone, cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, pregelatinized Starch etc.; Lubricant is selected from stearic acid, magnesium stearate, Pulvis Talci, sodium lauryl sulphate and micropowder silica gel etc.; Framework material in the compositions can be selected methylcellulose, sodium carboxymethyl cellulose, ethyl cellulose, hypromellose, acrylic resin, sodium alginate etc.; Correctives can select that A Siba is sweet, essence for organi juice, Herba Menthae essence, strawberry essence; Coloring agent can be selected carmine, sunset yellow, Fructus Citri junoris Huang etc.
For soft capsule, its filler is then selected the non-aqueous matrix of oils or other permissions as required for use, can use vegetable oil, as soybean oil, Oleum Arachidis hypogaeae semen, salad wet goods, also can be Oleum Ricini, cod-liver oil, propylene glycol, PEG-400 etc., need to add a certain amount of suspending agent (Cera Flava, stearic acid etc.) or fluidizer (as Tween-60, tween 80 or Arlacel-65 etc.) in case of necessity.
Enteric coatings material among the present invention comprises cellulose acetate phthalate ester, hydroxypropyl methyl cellulose phthalate, enteric solubility acrylic resin (I, II, III number) etc.
The present invention also provides this preparation of drug combination method, can both can adopt direct powder compression according to the operation of galenic pharmacy routine techniques method, can adopt wet granulation again; Enteric coated preparation or slow releasing preparation can make at ordinary tablet or capsule outsourcing film-coat.
The present invention also provides the method with anti-platelet aggregation medicine, Monas cuspurpureus Went extract medicine and hepatic therapeutic alliance myocardial infarction, angina pectoris and hyperlipidemia.The amount of the drug regimen of clopidogrel, Monas cuspurpureus Went extract and bifendate can be 30～150mg: 100～500mg: 10～50mg.Said composition is applicable to the acute and chronic cardiovascular and cerebrovascular disease of treatment, the hyperlipemia that merges as myocardial infarction, angina pectoris, coronary heart disease, cerebral thrombosis, cerebral infarction, cerebral ischemia, hypercholesterolemia, mix type hypercholesterolemia, atherosclerosis, nephrotic syndrome hyperlipemia, diabetes etc.
Following data declaration beneficial effect of the present invention by experiment:
The synergism of medicine
The compound recipe clopidogrel Monas cuspurpureus Went extract preparation of our exploitation is primarily aimed at platelet aggregation, dysbolism of blood fat problem in coronary heart disease, angina pectoris, atherosclerosis and the various cardiovascular and cerebrovascular disease.Simultaneously, add and used the transaminase lowering medicine to form compound preparation in order to intervene component for reducing blood fat in the Monas cuspurpureus Went extract to the influence that serum transaminase raises.New experimental data shows, this several drugs coupling is to reducing thrombosis, the blood fat reducing level, and the liver protecting function is alleviated coronary heart disease, angina pectoris has tangible effect, and the cardiovascular and cerebrovascular vessel accident is played prevention too and reduced the effect that takes place.
One 600 routine patient participate at random, in the clinical trial of double blinding, contrast, use Monas cuspurpureus Went extract+clopidogrel+bifendate and treat, prove the several drugs use in conjunction, the synergism that is had.All patients all suffer from the disease for cardiovascular and cerebrovascular vessel embolics such as arteriosclerosis, coronary heart disease or myocardial infarctions, be divided into 3 groups at random, every group 200 example, treatment group (compound recipe clopidogrel Monas cuspurpureus Went extract bifendate, 75/300/25mg/ day, every day 2 times), matched group I (clopidogrel, 75mg/ day, every day 2 times), control Group II (Monas cuspurpureus Went extract group 300mg/ day, every day 2 times).Result's demonstration is analysed in credit by statistics, in treatment coronary heart disease case fatality rate, reduce low-density lipoprotein cholesterol, serum total cholesterol, triglyceride, and aspect such as high density lipoprotein increasing, the treatment group has remarkable advantages (P＜0.05) for 2 matched groups of independent medication, ratio matched group I, II that serum transaminase raises are respectively 2.8 and 1.9%, the ratio that treatment group serum transaminase raises is 0.6%, and both compare has tangible statistical significance (P＜0.05).This shows that clopidogrel and Monas cuspurpureus Went extract two medical instruments have synergism.Renal function before and after the treatment, hematuria, the equal Non Apparent Abnormality of stool routine do not have other serious adverse effects yet and take place, and visible bifendate has been protected liver function, has avoided the side effect of medicine effectively.
Pharmaceutical composition of the present invention can be used for treating the cardiovascular and cerebrovascular vessel thrombotic disease and comprises: myocardial infarction, angina pectoris, coronary heart disease, cerebral thrombosis, cerebral infarction, cerebral ischemia etc.Hyperlipemia: hypercholesterolemia, mix type hypercholesterolemia, atherosclerosis, nephrotic syndrome hyperlipemia, diabetes merge hyperlipemia etc.Several drugs cooperatively interacts, and effect is collaborative, and few side effects has beat all effect, has obtained patient's welcome, and technology of the present invention is simple, and is easy to operate, is fit to large-scale production.
Pharmaceutical composition of the present invention, its dosage and administration is: adult's usual amounts is oral: starting dose is I, II and IV, V side, reaches therapeutic effect as 2 Zhou Houwei, rises to III and VI.Every day 2 times, to take after the meal, dosage can be adjusted as required.
The specific embodiment:
Further specify the present invention by the following examples, but not as limitation of the present invention.
Embodiment 1: preparation clopidogrel+Monas cuspurpureus Went extract sheet
Prescription: prepare 1000 prescription consumption
Clopidogrel 75g
Monas cuspurpureus Went extract 300g
Microcrystalline Cellulose 105g
Carboxymethyl starch sodium 20g
Polyvinylpyrrolidone 8g
Micropowder silica gel 4g
Magnesium stearate 2g
Preparation method: medicine and excipient are crossed 80 mesh sieves respectively, take by weighing recipe quantity Monas cuspurpureus Went extract, clopidogrel, bifendate, microcrystalline Cellulose, carboxymethyl starch sodium (2/3), mix homogeneously, polyvinylpyrrolidone aqueous solution system soft material with 10%, cross 16 mesh sieves, dry, granulate adds residue (1/3) carboxymethyl starch sodium, micropowder silica gel, magnesium stearate, and tabletting promptly gets conventional tablet.
On the basis of conventional tablet, can make the enteric coatel tablets preparation through following operation.
The configuration of enteric liquid is as follows:
Prescription:
Effect
Hydroxypropyl methyl cellulose phthalate 28.7g coating polymer
Tween 80 5.4g film coating adjuvant
Ethanol 200ml organic solvent
Acetone 200ml organic solvent
Adopt coating pan to carry out coating.Operating condition:
Coating pan rotating speed 6～7r/min
The spraying of nozzle types depletion of QI
Shower nozzle size 0.4mm nozzle (45～60 degree angle)
Spray speed 80～110ml/min
Fluid pressure 60～80kg/cm
2
Aerofluxus flow velocity 140～160m
3/ min
Induction air flow ratio 130～150m
3/ min; 20 ℃
40～60% relative humiditys
About 30min of coating time
Embodiment 2: preparation clopidogrel+Monas cuspurpureus Went extract dispersible tablet
Prescription: prepare 1000 prescription consumption
Clopidogrel 75g
Monas cuspurpureus Went extract 200g
Microcrystalline Cellulose 180g
PPVP 40g
L-HPC 9g
Aspartame 2.5g
Fructus Citri Limoniae essence 1.0g
Pulvis Talci 4.5g
Starch slurry is an amount of
Preparation method: medicine and adjuvant are crossed 80 mesh sieves respectively, after taking by weighing recipe quantity Monas cuspurpureus Went extract, clopidogrel, bifendate, mannitol, microcrystalline Cellulose, abundant mix homogeneously, add an amount of starch slurry and make soft material, 16 mesh sieves are granulated, and 80 ℃ of dryings are after 3 hours, 16 mesh sieve granulate, outer disintegrating agent PPVP, L-HPC, correctives aspartame, Fructus Citri Limoniae essence, the lubricant Pulvis Talci of adding, behind the mixing, be pressed into dispersible tablet.Embodiment 3: preparation clopidogrel+Monas cuspurpureus Went extract chewable tablet
Prescription: prepare 1000 prescription consumption
Clopidogrel 75g
Monas cuspurpureus Went extract 250g
Starch 40g
Microcrystalline Cellulose 42g
Citric acid 2.5g
Aspartame 1.5g
Pulvis Talci 4g
The 5%PVP50% alcoholic solution is an amount of
Preparation method: medicine and adjuvant are crossed 80 mesh sieves respectively, after taking by weighing recipe quantity Monas cuspurpureus Went extract, clopidogrel, bifendate, starch, microcrystalline Cellulose, abundant mix homogeneously, add an amount of 5%PVP50% alcoholic solution and make soft material, 16 mesh sieves are granulated, 80 ℃ of dryings are after 3 hours, and 14 mesh sieve granulate add correctives aspartame, citric acid, lubricant Pulvis Talci outward, behind the mixing, be pressed into chewable tablet.
Embodiment 4: preparation clopidogrel+Monas cuspurpureus Went extract capsule
Prescription: prepare 1000 prescription consumption
Clopidogrel 150g
Monas cuspurpureus Went extract 200g
Microcrystalline Cellulose 15g
CMS-Na 3.0g
Micropowder silica gel 5.0g
Preparation method: medicine and adjuvant are crossed 80 mesh sieves respectively, take by weighing recipe quantity Monas cuspurpureus Went extract, clopidogrel, bifendate, microcrystalline Cellulose, CMS-Na, micropowder silica gel, be loaded on and promptly get conventional capsule in the capsule shells; After being filled into soft capsule shell, promptly get soft capsule; After being filled into enteric capsule shell, promptly get enteric coated capsule.
Embodiment 5: preparation clopidogrel+Monas cuspurpureus Went extract granule
Prescription: prepare 1000 bags prescription consumption
Clopidogrel 150g
Monas cuspurpureus Went extract 300g
Sucrose 200g
Dextrin 120g
Sunset yellow 0.10g
Flavoring pineapple essence 5g
The 3%PVP75% alcoholic solution is an amount of
Preparation method: medicine and adjuvant are crossed 80 mesh sieves respectively, after taking by weighing recipe quantity Monas cuspurpureus Went extract, clopidogrel, bifendate, sucrose, dextrin, the abundant mix homogeneously of flavoring pineapple essence, other gets sunset yellow and joins in an amount of 3%PVP75% alcoholic solution, after being uniformly dispersed, make soft material, 16 mesh sieves are granulated, and 80 ℃ of dryings are after 2～3 hours, 14 mesh sieve granulate are distributed into 1000 bags.
Embodiment 6: preparation clopidogrel+Monas cuspurpureus Went extract+Bifendate Tablet
Prescription: prepare 1000 prescription consumption
Clopidogrel 75g
Monas cuspurpureus Went extract 300g
Bifendate 25g
Microcrystalline Cellulose 105g
Carboxymethyl starch sodium 20g
Polyvinylpyrrolidone 8g
Micropowder silica gel 4g
Magnesium stearate 2g
Preparation method: medicine and excipient are crossed 80 mesh sieves respectively, take by weighing recipe quantity Monas cuspurpureus Went extract, clopidogrel, bifendate, microcrystalline Cellulose, carboxymethyl starch sodium (2/3), mix homogeneously, polyvinylpyrrolidone aqueous solution system soft material with 10%, cross 16 mesh sieves, dry, granulate adds residue (1/3) carboxymethyl starch sodium, micropowder silica gel, magnesium stearate, and tabletting promptly gets conventional tablet.
On the basis of conventional tablet, can make the enteric coatel tablets preparation through following operation.The configuration of enteric liquid can be with reference to aforementioned content.
Embodiment 7: preparation clopidogrel+Monas cuspurpureus Went extract+bifendate dispersible tablet
Prescription: prepare 1000 prescription consumption
Clopidogrel 75g
Monas cuspurpureus Went extract 200g
Bifendate 25g
Microcrystalline Cellulose 180g
PPVP 40g
L-HPC 9g
Aspartame 2.5g
Fructus Citri Limoniae essence 1.0g
Pulvis Talci 4.5g
Starch slurry is an amount of
Preparation method: medicine and adjuvant are crossed 80 mesh sieves respectively, after taking by weighing recipe quantity Monas cuspurpureus Went extract, clopidogrel, bifendate, mannitol, microcrystalline Cellulose, abundant mix homogeneously, add an amount of starch slurry and make soft material, 16 mesh sieves are granulated, and 80 ℃ of dryings are after 3 hours, 16 mesh sieve granulate, outer disintegrating agent PPVP, L-HPC, correctives aspartame, Fructus Citri Limoniae essence, the lubricant Pulvis Talci of adding, behind the mixing, be pressed into dispersible tablet.
Embodiment 8: preparation clopidogrel+Monas cuspurpureus Went extract+bifendate chewable tablet
Prescription: prepare 1000 prescription consumption
Clopidogrel 75g
Monas cuspurpureus Went extract 250g
Bifendate 25g
Starch 40g
Microcrystalline Cellulose 42g
Citric acid 2.5g
Aspartame 1.5g
Pulvis Talci 4g
The 5%PVP50% alcoholic solution is an amount of
Preparation method: medicine and adjuvant are crossed 80 mesh sieves respectively, after taking by weighing recipe quantity Monas cuspurpureus Went extract, clopidogrel, bifendate, starch, microcrystalline Cellulose, abundant mix homogeneously, add an amount of 5%PVP50% alcoholic solution and make soft material, 16 mesh sieves are granulated, 80 ℃ of dryings are after 3 hours, and 14 mesh sieve granulate add correctives aspartame, citric acid, lubricant Pulvis Talci outward, behind the mixing, be pressed into chewable tablet.
Embodiment 9: preparation clopidogrel+Monas cuspurpureus Went extract+Bifendate
Prescription: prepare 1000 prescription consumption
Clopidogrel 150g
Monas cuspurpureus Went extract 200g
Bifendate 25g
Microcrystalline Cellulose 15g
CMS-Na 3.0g
Micropowder silica gel 5.0g
Preparation method: medicine and adjuvant are crossed 80 mesh sieves respectively, take by weighing recipe quantity Monas cuspurpureus Went extract, clopidogrel, bifendate, microcrystalline Cellulose, CMS-Na, micropowder silica gel, be loaded on and promptly get conventional capsule in the capsule shells; After being filled into soft capsule shell, promptly get soft capsule; After being filled into enteric capsule shell, promptly get enteric coated capsule.
Embodiment 10: preparation clopidogrel+Monas cuspurpureus Went extract+bifendate granule
Prescription: prepare 1000 bags prescription consumption
Clopidogrel 150g
Monas cuspurpureus Went extract 300g
Bifendate 25g
Sucrose 200g
Dextrin 120g
Sunset yellow 0.10g
Flavoring pineapple essence 5g
The 3%PVP75% alcoholic solution is an amount of
Preparation method: medicine and adjuvant are crossed 80 mesh sieves respectively, after taking by weighing recipe quantity Monas cuspurpureus Went extract, clopidogrel, bifendate, sucrose, dextrin, the abundant mix homogeneously of flavoring pineapple essence, other gets sunset yellow and joins in an amount of 3%PVP75% alcoholic solution, after being uniformly dispersed, make soft material, 16 mesh sieves are granulated, and 80 ℃ of dryings are after 2～3 hours, 14 mesh sieve granulate are distributed into 1000 bags.
Claims (10)
1, a kind of pharmaceutical composition that prevents or treat acute and chronic cardiovascular and cerebrovascular disease is characterized in that said composition contains Monas cuspurpureus Went extract and at least a anti-platelet aggregation medicine and/or at least a hepatic for the treatment of effective dose.
2, the pharmaceutical composition of claim 1, it is characterized in that described anti-platelet aggregation medicine is selected from: aspirin, troxerutin, dipyridamole, clofibrate, ticlopidine, sulfinpyrazone, cilostazol, indobufen, clopidogrel, ozagrel, epoprostenol, Beraprost or dazoxiben; Hepatic can be selected from: bifendate, adenosine triphosphate disodium salt, inosine, glucuronolatone, diisopropylamine dichloroacetate or have the vitamin of hepatoprotective effect.
3, the pharmaceutical composition of claim 2 is characterized in that, described compositions contains Monas cuspurpureus Went extract, clopidogrel and/or bifendate.
4, the pharmaceutical composition of claim 3 is that the dosage form with unit dose exists, and the Monas cuspurpureus Went extract of 100～500mg is contained in each preparation unit, the clopidogrel of 30～150mg, and/or the bifendate of 10～50mg.
5, the pharmaceutical composition of claim 4 is characterized in that, described compositions contains the Monas cuspurpureus Went extract of 200～400mg, the clopidogrel of 50～100mg, and/or the bifendate of 110～30mg.
6, the pharmaceutical composition of claim 5 is characterized in that, the amount that described compositions contains Monas cuspurpureus Went extract and clopidogrel is as follows:
Clopidogrel (mg) 75 75 75 150 150 150
Monas cuspurpureus Went extract (mg) 200 250 300 200 250 300
7, the pharmaceutical composition of claim 6 is characterized in that, the amount that described compositions contains Monas cuspurpureus Went extract and clopidogrel and/or bifendate is as follows:
Clopidogrel (mg) 75 75 75 150 150 150
Monas cuspurpureus Went extract (mg) 200 250 300 200 250 300
Bifendate (mg) 25 25 25 25 25 25
8, the pharmaceutical composition of claim 1 is characterized in that, described compositions is to be fit to medicinal any peroral dosage form.
9, the pharmaceutical composition of claim 1 is characterized in that, described peroral dosage form can be selected from conventional tablet, enteric coatel tablets, chewable tablet, dispersible tablet, conventional capsule, soft capsule, enteric coated capsule, granule.
10, the pharmaceutical composition of claim 1 is in preparation prevention or treat application in the medicine of acute and chronic diseases of cardiovascular and cerebrovascular systems.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510084327 CN1720941A (en) | 2005-07-18 | 2005-07-18 | Compound medicinal preparation with clopidogrel and red rice extracts and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510084327 CN1720941A (en) | 2005-07-18 | 2005-07-18 | Compound medicinal preparation with clopidogrel and red rice extracts and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1720941A true CN1720941A (en) | 2006-01-18 |
Family
ID=35911777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510084327 Pending CN1720941A (en) | 2005-07-18 | 2005-07-18 | Compound medicinal preparation with clopidogrel and red rice extracts and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1720941A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101879169A (en) * | 2010-07-09 | 2010-11-10 | 西安力邦制药有限公司 | Compound preparation for treating relevant vascular diseases and preparation method thereof |
| CN101073602B (en) * | 2006-05-15 | 2011-05-11 | 成都地奥九泓制药厂 | Medicinal composition for treating or improving liver function, its production and use |
-
2005
- 2005-07-18 CN CN 200510084327 patent/CN1720941A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101073602B (en) * | 2006-05-15 | 2011-05-11 | 成都地奥九泓制药厂 | Medicinal composition for treating or improving liver function, its production and use |
| CN101879169A (en) * | 2010-07-09 | 2010-11-10 | 西安力邦制药有限公司 | Compound preparation for treating relevant vascular diseases and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1195511C (en) | The use of fumaric acid derivatives in transplant medicine | |
| CN1682719A (en) | Enteric soluble coating slow releasing tablet containing huperzine A and preparing method | |
| CN1245398C (en) | Extraction technology of baicalein, medicinal composition and preparation technology of medicine | |
| CN1720941A (en) | Compound medicinal preparation with clopidogrel and red rice extracts and application thereof | |
| CN1903194A (en) | Slow-release, controlled-release prepn. of simvastatin, and method for preparing same | |
| JP2010270111A (en) | Arginine-containing tablet | |
| CN1946376A (en) | Coated tablet composition and method of manufacturing the same | |
| CN101028518A (en) | Medicinal composition containing silver ester medicine and ibobulodine | |
| CN103239449A (en) | Ezetimibe, simvastatin and nicotinic acid compound preparation and preparation method of ezetimibe, simvastatin and nicotinic acid compound preparation | |
| CN1660321A (en) | Medicinal preparation of extractive from compound aspirin and rice fermentred with red yeast | |
| CN1188131C (en) | Orally taken pulsed releasing system of phenyl diazepine medicine and its prepn. | |
| CN1718566A (en) | Ferulaic acid and its sodium salt used for preventing and treating senile dementia medicine | |
| CN1543943A (en) | Oral silybin sustained release agent and preparation thereof | |
| CN1287860C (en) | Combination of medication containing reductase inhibitor HMG CoA and Melatonin | |
| CN1803144A (en) | Pharmaceutical composition containing clofibrate compound and B family vitamin | |
| CN1660320A (en) | Extractive of compound rice fermented with red yeast and preparation of hepatic protectant and application | |
| CN1651086A (en) | Compound red yeast extract medicinal preparation and its application | |
| CN1651042A (en) | Compound aspirin red yeast extract medicinal preparation and its application | |
| CN1660432A (en) | Preparation of compound Tatin class and hepatic protectant and applications | |
| CN1650981A (en) | Compound red leaven extract medicinal preparation and its application | |
| CN1608623A (en) | Enteric coated donepezil hydrochloride tablet and its perpn process | |
| CN1309376C (en) | Musk slow-controlled release preparation and preparation method thereof | |
| CN1850063A (en) | Composition containing fibrate drug and taurine | |
| CN1827170A (en) | Composition containing dihydropyridin type of calcium antagonists and fibrates medicine | |
| CN115054583A (en) | Policosanol Ezetimibe compound preparation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |